Parnax Lab Ltd
NSE: BSE: 506128
₹129.90
(-0.08%)
Tue, 17 Mar 2026, 01:26 am
Market Cap1.48B
PE Ratio11.90
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KParnax Lab Analysis
dividend
- Unable to evaluate Parnax Lab's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Parnax Lab's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Parnax Lab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Parnax Lab has been profitable on average in the past, therefore cash runway is not a concern.
- Parnax Lab has been profitable on average in the past, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (21.9%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1x debt.
- Parnax Lab's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (138.8% vs 109.9% today).
- Parnax Lab is making a loss, therefore interest payments are not well covered by earnings.
- Parnax Lab's level of debt (109.9%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Parnax Lab board of directors is about average.
- Prakash's remuneration is about average for companies of similar size in India.
- The tenure for the Parnax Lab management team is about average.
- Prakash's compensation has increased whilst company is loss making.
misc
- Parnax Lab is not covered by any analysts.
- Parnax Lab has significant price volatility in the past 3 months.
past
- Unable to compare Parnax Lab's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Parnax Lab does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Parnax Lab used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- It is difficult to establish if Parnax Lab improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Parnax Lab has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Parnax Lab's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Parnax Lab is good value based on assets compared to the IN Pharmaceuticals industry average.
- Parnax Lab is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Parnax Lab is loss making, we can't compare the value of its earnings to the India market.
- 506128 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 506128 underperformed the Market in India which returned -14.5% over the past year.
- BSE:506128 is down -12.3% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:506128 is down -12.3% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800